Skip to main content

Advertisement

Table 3 Summary of outcomes reported of trastuzumab beyond disease progression series

From: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer

Study by country Patients, number ORR, percentage CBR, percentage TTP, months OS, months
  First Second First Second First Second First Second   
  HaltT RetT        HaltT RetT
Global [18] 77 65 39 32 69 54 5.5 6.1   
   105        nr 29
Hellenic [16]   80 nr 24 nr 52 nr 5.2   
   80        nr 22.2
German [14] 23 23 56.6 39.1 nr nr nr nr   
  113 23        38.5a 62.4a
Austrian [21] 54 nr 42.6 25.9 85.2 68.5 6.0 6.0   
          nr nr
Spanish [17] 93 47 46.6 29.8 71 51.1 5.0 4.0   
          nr nr
French [15]    nr nr nr nr nr nr   
  70 107        4.6b NRb
Italian 1 [20] 184 40 55.4 17.9 nr nr 9.0 6.3   
  71 40        30.2b 30.1b
Italian 2 [19] 59 37 59.3 27 83 62.2 9.5 6.7   
          nr nr
Italian 3 57 55 36 17 73 55 7.25 5.25   
  23 59        29.9b 42.3b
  1. aOS is calculated from the diagnosis of metastatic disease to the documented date of death. bOS is calculated from the day of the first administration of trastuzumab-based therapy to the documented date of death. CBR, clinical benefit rate; HaltT, patients halting trastuzumab; nr, not reported; NR, not reached after median follow-up of 27.8 months; ORR, objective response rate; OS, overall survival; RetT: patients retaining trastuzumab; TTP, time to progression.